Home › Research › Health systems and care delivery
Risk of first ischaemic stroke and use of antidopaminergic antiemetics: nationwide case-time-control study
Bénard-Laribière Anne, Hucteau Emilie, Debette Stéphanie, Kirchgesner Julien, Bezin Julien, Pariente Antoine. BMJ (Clinical research ed.), 2022-03-25
Topic: Risk, prevention and care in population studies
Plain-language summary
To estimate the risk of ischaemic stroke associated with antidopaminergic antiemetic (ADA) use. Case-time-control study. Data from the nationwide French reimbursement healthcare system database Système National des Données de Santé (SNDS). Eligible participants were ≥18 years with a first ischaemic stroke between 2012 and 2016 and at least one reimbursement for any ADA in the 70 days before stroke. Frequencies of ADA reimbursements were compared for a risk period (days -14 to -1 before stroke) and three matched reference periods (days -70 to -57, -56 to -43, and -42 to -29) for each patient. Time trend of ADA use was controlled by using a control group of 21 859 randomly selected people free of the event who were individually matched to patients with stroke according to age, sex, and risk factors of ischaemic stroke. Association between ADA use and risk of ischaemic stroke was assessed by estimating the ratio of the odds ratios of exposure evaluated in patients with stroke and in controls. Analyses were adjusted for time varying confounders (anticoagulants, antiplatelets, and prothrombotic or vasoconstrictive drugs). Among the 2612 patients identified with incident stroke, 1250 received an ADA in the risk period and 1060 in the reference periods. The comparison with the 5128 and 13 165 controls who received an ADA in the same periods yielded a ratio of adjusted odds ratios of 3.12 (95% confidence interval 2.85 to 3.42). Analyses stratified by age, sex, and history of dementia showed similar results. Ratio of adjusted odds ratios for analyses stratified by ADA was 2.51 (2.18 to 2.88) for domperidone, 3.62 (3.11 to 4.23) for metopimazine, and 3.53 (2.62 to 4.76) for metoclopramide. Sensitivity analyses suggested the risk would be higher in the first days of use. Using French nationwide exhaustive reimbursement data, this self-controlled study reported an increased risk of ischaemic stroke with recent ADA use. The highest increase was found for metopimazine and metoclopramide.
What this study adds
Evidence grade: Low
The record lists 2,612 participants. This study found an increased risk of ischaemic stroke with recent use of antidopaminergic antiemetic medicines, and results were similar in people with a history of dementia. It is about stroke risk from these medicines, not about treating, curing, or preventing Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Anne, B.-L., Emilie, H., Stéphanie, D., Julien, K., Julien, B., & Antoine, P. (2022). Risk of first ischaemic stroke and use of antidopaminergic antiemetics: nationwide case-time-control study. BMJ (Clinical research ed.). https://doi.org/10.1136/bmj-2021-066192
Vancouver
Anne B.-L, Emilie H, Stéphanie D, Julien K, Julien B, Antoine P. Risk of first ischaemic stroke and use of antidopaminergic antiemetics: nationwide case-time-control study. BMJ (Clinical research ed.). 2022. doi:10.1136/bmj-2021-066192. PMID: 35321876.
BibTeX
@article{anne2022-35321876,
author = {Anne, Bénard-Laribière and Emilie, Hucteau and Stéphanie, Debette and Julien, Kirchgesner and Julien, Bezin and Antoine, Pariente},
title = {{Risk of first ischaemic stroke and use of antidopaminergic antiemetics: nationwide case-time-control study}},
journal = {BMJ (Clinical research ed.)},
year = {2022},
doi = {10.1136/bmj-2021-066192},
pmid = {35321876},
url = {https://doi.org/10.1136/bmj-2021-066192}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- To estimate the risk of ischaemic stroke associated with antidopaminergic antiemetic (ADA) use.
- Analyses stratified by age, sex, and history of dementia showed similar results.
- Using French nationwide exhaustive reimbursement data, this self-controlled study reported an increased risk of ischaemic stroke with recent ADA use.
Why it matters
This study found an increased risk of ischaemic stroke with recent use of antidopaminergic antiemetic medicines, and results were similar in people with a history of dementia. It is about stroke risk from these medicines, not about treating, curing, or preventing Alzheimer's disease.
Study details
- Participants2,612
- Evidence strengthLow
How this study scored 45/100
Published in a leading specialty journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 43 of the 96 points we could judge it on, which is 45 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (BMJ (Clinical research ed.)) |
| Journal's citation record | 3 / 4 | BMJ: journal h-index 413 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 3 / 4 | 2,612 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 10 times (OpenAlex, 2026-10-17) |
| Citations per year | 1 / 5 | 1.7 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 2 / 6 | Cited 1.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 2 / 3 | Inserm: institution h-index 1,988 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35321876) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 43 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 43 of the 96 points we could judge it on is 45 out of 100. |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Health systems and care delivery from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.